Leon Recanati Buys 460,000 Shares of Evogene (NASDAQ:EVGN) Stock

Posted by Brian Himes on Aug 15th, 2026

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) Director Leon Recanati acquired 460,000 shares of the stock in a transaction on Tuesday, August 11th. The shares were acquired at an average price of $0.64 per share, with a total value of $294,400.00. Following the transaction, the director directly owned 1,343,886 shares of the company’s stock, valued at $860,087.04. The trade was a 52.04% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Evogene Stock Down 7.7%

Shares of NASDAQ:EVGN opened at $0.60 on Friday. Evogene Ltd. has a 52 week low of $0.37 and a 52 week high of $1.50. The stock has a market capitalization of $5.24 million, a P/E ratio of -0.43 and a beta of 1.40. The firm has a fifty day simple moving average of $0.53 and a two-hundred day simple moving average of $0.72.

Evogene (NASDAQ:EVGN – Get Free Report) last announced its earnings results on Saturday, May 16th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.33). Evogene had a negative net margin of 638.12% and a negative return on equity of 158.82%. The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.35 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC increased its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,387 shares during the last quarter. Citadel Advisors LLC lifted its holdings in shares of Evogene by 169.4% in the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 36,206 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Evogene in the 4th quarter worth about $25,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Evogene currently has a consensus rating of “Sell”.

Read Our Latest Stock Report on Evogene

Evogene Company Profile

(Get Free Report)

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.